FDA Approves First Device to Treat Rheumatoid Arthritis Without Medication: A Paradigm Shift

In an unprecedented milestone for autoimmune disease management, the U.S. Food and Drug Administration (FDA) has officially approved the SetPoint System, a first-in-class neuroimmune modulation implant designed to treat moderately to severely active rheumatoid arthritis (RA) without the use of conventional drugs. This breakthrough introduces an innovative therapeutic option for patients who cannot tolerate or do not respond to standard immunosuppressive therapies.

A New Era for Autoimmune Treatment

On July 31, 2025, the FDA granted marketing clearance to SetPoint Medical, a California-based medtech company, for its implantable vagus nerve stimulation device. Unlike biologics or disease-modifying antirheumatic drugs (DMARDs), the SetPoint System leverages bioelectronic medicine to regulate the immune system through precise, daily nerve stimulation.

“The approval of the SetPoint System, the first-in-class neuroimmune modulation platform, represents a transformative milestone in the management of autoimmune diseases,” said Murthy V. Simhambhatla, Ph.D., CEO of SetPoint Medical.

This new device offers a non-pharmacological alternative for the 1.5 million Americans living with RA—particularly the many patients for whom current medications provide insufficient relief or trigger adverse side effects.

How the SetPoint System Works

The SetPoint System is a miniaturized, wireless implant placed just under the skin in the neck region, where it interfaces with the vagus nerve, a major conduit of communication between the brain and vital organs. Once implanted through a minimally invasive outpatient procedure, the system is programmed to deliver one-minute electrical pulses daily, aiming to stimulate the inflammatory reflex—a natural mechanism that helps control immune response.

Key specifications include:

• Battery life of up to 10 years, with simple, weekly transdermal charging

• No systemic immunosuppression, reducing the risk of infection or malignancy

• Remote device programming via secure clinical interfaces

“After implantation during a minimally invasive outpatient procedure, the device is programmed to automatically administer therapy daily for up to ten years,” explained Dr. Mark Richardson, MD, PhD, Director of Functional Neurosurgery at Massachusetts General Hospital and co-lead investigator of the pivotal study.

Evidence from the RESET-RA Trial

The FDA approval was based on results from the RESET-RA trial, a randomized, double-blind, sham-controlled multicenter study involving 242 participants with active RA unresponsive to previous biologic or synthetic DMARDs.

Highlights from the clinical data:

• Primary endpoint met: ACR 20 response at 12 weeks

• By 12 months, over 75% of participants in the active group had discontinued DMARDs while maintaining symptom relief

• No significant adverse events related to stimulation or the implant procedure

“The RESET RA study met its primary endpoint of ACR 20 at three months, and over 75% of the treatment group remained free from biologic or synthetic DMARDs at one year,” noted Dr. John Tesser, MD, FACP, FACR, national principal investigator for the trial.

The trial results not only underscore the safety of neuromodulation in RA but also demonstrate its durability and scalability as a chronic disease solution.

Why This Matters

1. Transformative for Rheumatoid Arthritis Care

Traditional RA treatments such as TNF inhibitors, methotrexate, and JAK inhibitors are effective but carry risks like infection, liver damage, and cancer. Moreover, treatment fatigue and loss of efficacy are common—over 50% of RA patients discontinue biologic therapy within two years due to inefficacy or adverse effects.

The SetPoint System addresses these challenges by offering:

• Drug-free symptom control

• Minimal side effects

• Lower long-term cost of care

2. Implications for Other Autoimmune Conditions

The success of the SetPoint System in RA opens doors for neuroimmune therapy in diseases like:

• Inflammatory bowel disease (IBD)

• Lupus

• Multiple sclerosis

• Psoriasis

SetPoint Medical is already exploring additional indications with plans to expand trials and regulatory filings in 2026.

3. Impact on Surgical and Ambulatory Care Markets

With the system implantable in ambulatory surgical centers (ASCs) under local anesthesia, hospitals and specialty clinics are expected to adopt this approach quickly. Providers must begin:

• Training surgical teams

• Educating rheumatologists

• Coordinating reimbursement models

Device makers, distributors, and insurers will also need to accommodate the increased demand for implantable immunomodulation therapies.

Regulatory, Clinical, and Commercial Outlook

With FDA clearance now granted, SetPoint Medical is launching a phased commercial rollout beginning in major U.S. cities, followed by national expansion in early 2026. The company will be collecting post-marketing surveillance data and working with key opinion leaders to optimize implementation protocols.

The Centers for Medicare and Medicaid Services (CMS) is expected to issue new reimbursement guidelines for the SetPoint procedure by Q1 2026, potentially including hospital outpatient department (HOPD) and ASC coverage.

The FDA’s approval of the SetPoint System represents a historic breakthrough in the way we approach chronic inflammatory diseases. By tapping into the body’s natural neural pathways, the device redefines how rheumatoid arthritis can be treated—not by suppressing the immune system with drugs, but by modulating it through bioelectronic stimulation.

For patients, this means a safer, longer-lasting, and more tolerable alternative. For the medical community, it signals the beginning of a new era in neuroimmune medicine.

As clinical adoption accelerates and data accumulates, the SetPoint System may soon serve as the template for next-generation treatment across the autoimmune spectrum—combining the best of neurosurgery, immunology, and biomedical engineering in one revolutionary device.